Japer Therapeutics Warrants
JSPRW
25 hedge funds and large institutions have $3.37M invested in Japer Therapeutics Warrants in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
81% more capital invested
Capital invested by funds: $1.86M → $3.37M (+$1.5M)
39% more funds holding
Funds holding: 18 → 25 (+7)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
+$58.5K |
| 2 |
LIM
Longfellow Investment Management
Boston,
Massachusetts
|
+$58.4K |
| 3 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$40.9K |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$31.3K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$18.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$64.1K |
| 2 |
CAC
Cowen and Company
New York
|
-$36.8K |
| 3 |
MSU
Mizuho Securities USA
New York
|
-$11K |
| 4 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$5.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$52 | +83 | New |
|
JSPRW Hedge Fund Activity: Q2 2020 in Review
25 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q2 2020, worth a combined $3.37M — up 81% from $1.86M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new JSPRW positions and 1 closed out — a net gain of 7 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Bulldog Investors, opening a new position worth an estimated $58.5K. The largest seller was Geode Capital Management, cutting an estimated $64.1K.
- 25 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q2 2020, up from 18 in Q1 2020.
- Funds reported $3.37M of Japer Therapeutics Warrants stock for Q2 2020, up 81% quarter-over-quarter.
- 8 funds opened new Japer Therapeutics Warrants positions in Q2 2020 and 1 closed out, a net change of +7 holders.
- The largest Japer Therapeutics Warrants buyer in Q2 2020 was Bulldog Investors, an estimated $58.5K added.
- The largest Japer Therapeutics Warrants seller in Q2 2020 was Geode Capital Management, an estimated $64.1K sold.
Based on aggregated 13F filings for Q2 2020.